Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

In a meta‐analysis of RCTs and open label studies, the TNFα blocker infliximab was associated with slightly more adverse events compared to placebo (OR 1.55, 95% CI 1.01–2.35), although this did not reach statistical significance for other biologics (Singh et al., 2011 ).

also in 111,027 other papers